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Background: There is considerable public interest in whether Europe is facing an 
opioid crisis comparable to the one in the United States and the contribution of opioid 
prescriptions for pain to a potential opioid crisis.
Methods: A task force of the European Pain Federation (EFIC) conducted a sur-
vey with its national chapter representatives on trends of opioid prescriptions and of 
drug- related emergency departments and substance use disorder treatment admis-
sions and of deaths as proxies of opioid- related harms over the last 20 years.
Results: Data from 25 European countries were received. In most European countries 
opioid prescriptions increased from 2004 to 2016. The levels of opioid consumption 
and their increase differed between countries. Some Eastern European countries still 
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1 |  INTRODUCTION
Over the past 20  years, increasing opioid prescribing for 
chronic pain has been reported in the United States and 
Canada, coinciding with an increase in illicit use of pre-
scribed opioids and opioid- related morbidity and mortality, 
the so- called ‘opioid crisis’. This crisis has been described as 
a ‘triple wave epidemic’ of deaths, arising from overlapping 
increases in mortality attributable to three classes of opioids: 
prescription opioids, heroin and novel synthetic illicit opioids 
(Ciccarone, 2019; deWeerdt, 2019).
In 2019, the Organisation for Economic Co- operation 
and Development (OECD) published a report ‘Addressing 
Problematic Opioid Use in OECD Countries’. The OECD 
report did not include all European countries. The report 
stated, that other OECD countries such as Australia and some 
European countries, have also begun to experience raising 
trends of opioid medicines consumption and overdose deaths 
(Organisation for Economic Co- operation & Development 
OECD,  2019). The report prompted a discussion about 
whether Europe would also be facing an opioid epidemic 
(Alho et al., 2020; Verhamme & Bohnen, 2019).
A recent review considering on whether Europe is fac-
ing an opioid crisis comparable to the US analysed data from 
four European countries (France, Germany, Netherlands and 
United Kingdom) (van Amsterdam et  al.,  2020) and con-
cluded there is no evidence of a current or emerging opioid 
crisis in these European countries although high rates of 
opioid- related harms were reported in Scotland. A survey on 
the availability of cannabis- based medicines reported a great 
variability in the availability and prescription of cannabis- 
based medicines for pain in Europe (Krcevski- Skvarc 
et al., 2018). Therefore, data from all European countries are 
warranted to assess if there is has been an increase in opioid 
prescriptions all over Europe.
In addition, an increase in opioid prescribing might rep-
resent satisfied unmet needs, e.g. in cancer pain management 
and palliative care. The OECD report did not provide data on 
the indications (e.g. acute pain, chronic noncancer pain, can-
cer pain) of opioid prescribing. Therefore, we need to know, 
for which indications opioids are prescribed in European 
countries.
Opioid overprescribing is considered one of the most im-
portant root causes of the first wave of the opioid crisis in 
North America (Ciccarone, 2019; deWeerdt, 2019). It is es-
timated that 8%- 12% of patients in the United States who are 
prescribed opioids for acute pain management will develop an 
opioid use disorder (National Institute of Drug Abuse, 2020). 
Of those who currently use illicit heroin, 80% have initially 
used prescription opioid analgesics for non- medical purposes 
(National Institute of Drug Abuse, 2020). In addition, an in-
crease in hospital admissions for opioids overdose, either by 
people prescribed these medicines for medical reasons or by 
people using prescription opioids illegally has been reported 
in the United States (deWeerdt, 2019). To determine the po-
tential role of opioid prescribing for opioid- related harms, 
we need to know the proportion of patients with chronic 
pain with prescribed opioids in opioid- related morbidity and 
mortality.
Because of the considerable public interest in the question, 
whether Europe is facing an opioid crisis, the European Pain 
Federation EFIC conducted a survey. In the survey, experts 
from European countries were asked if there is an opioid cri-
sis in their country and— if yes— prescribing of opioids for 
pain contributed to the crisis. In addition, a narrative review 
was performed in order to better address this issue.
have a low opioid consumption. Opioids are mainly prescribed for acute pain and 
chronic noncancer pain in some Western and Northern European countries. There was 
a parallel increase in opioid prescriptions and some proxies of opioid- related harms 
in France, Finland and the Netherlands, but not in Germany, Spain and Norway. 
In United Kingdom, opioid overdose deaths, but not opioid prescriptions increased 
between 2016 and 2018. There are no robust data available on whether prescribed 
opioids for pain patients contributed to opioid- related harms.
Conclusions: There are marked differences between European countries in trends 
of opioid prescribing and of proxies for opioid- related harms. Europe as a whole is 
not facing an opioid crisis. Discussions on the potential harms of opioids should not 
obstruct their prescription for cancer pain and palliative care.
Significance: Europe as a whole is not facing an opioid crisis. Some Eastern European 
countries have limited access to opioid medicines. Discussions on the potential harms 
of opioid medicines for noncancer pain should not obstruct opioid therapy for cancer 
therapy and palliative care.
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2 |  METHODS
The European Pain Federation (EFIC) is a multidisciplinary 
professional organization in the field of pain research and 
medicine, consisting of the 37 chapters of the International 
Association for the Study of Pain (IASP). The Federation's 
constituent chapters consist of Pain Societies from 37 pre-
dominately European countries, each represented by a coun-
cillor. The Executive Board of EFIC formed a task force in 
May 2020 to explore a potential opioid crisis in European 
countries. The task force members were recruited from 
EFIC’s task force to update its position paper on appropriate 
use of opioids for chronic noncancer pain (CNCP; for details 
see Häuser et al., 2021). The task force developed a question-
naire containing the questions outlined below.
Has there been a quantifiable increase in opioid prescrip-
tions over the past 20 years (2000– 2020)?
For which indications (e.g. acute pain therapy, cancer and 
palliative care, CNCP) were opioids prescribed?
How many people among the general population are on 
long- term prescribed opioid therapy for chronic noncancer 
pain (CNCP)?
Has there been an increase in the number of emergency 
visits and of deaths associated with opioids over the past 
20 years (2000– 2020)?
Has there been an increase in the number of deaths as-
sociated with opioids (all, including legally prescribed and 
illegally obtained, and both pharmaceutical and 'street drugs') 
over the past 20 years (2000– 2020)?
Has there been an increase in people (both with and with-
out chronic pain) misusing prescription opioids referred to 
addiction care services over the past 20 years (2000– 2020)?
The Federation office in Brussels sent out the question-
naire to each of its 37 councillors on 6 June 2020. In addition, 
they received a link to the questionnaire by Survey Monkey. 
The councillors could reply by email and/or the link within 
3 weeks. Based on our experiences with a survey on cannabis- 
based medicines we did not send out a second request and did 
not contact a vice councillor in case of non- response. The 
members of the task force asked a pain specialist from some 
countries whom they knew personally to complete the survey, 
too. Councillors and other contacted pain specialists were 
asked to provide references (publications in peer reviewed 
journals and/or national databases) for their answers. In case 
of discrepancy of answers obtained by councillors and pain 
specialists of the same country, we preferred answers based 
on publications in peer- reviewed journals and/ or national da-
tabases over personal impressions.
Data from the European Monitoring Centre for Drugs 
and Drug Addiction are reported in a separate paper (Seyler 
et al., 2021). In the Section 3, we report data which are not 
included in the European Drug Report 2019 (European 
Monitoring Centre for Drugs & Drug Addiction, 2019).
We assumed a relevant increase/decrease in the outcome 
if there was a >10% change per time period analysed.
We will use the following terms in the Section 3:
Drug consumption can be expressed in cost, number of 
units, number of prescriptions or by the physical quantity 
of drugs. However, these variables can vary between re-
gions and countries over time. This limits comparisons of 
drug consumption at an international level. To address this, 
a technical unit of measurement, the defined daily dose 
(DDD) was created. DDD is defined as the assumed average 
maintenance dose per day for a drug used for its main indica-
tion in adults. DDDs are only assigned for medicines given 
an Anatomical Therapeutic Chemical (ATC) Classification 
System codes. The DDDs are allocated to drugs by the WHO 
Collaborating Centre in Oslo (World Health Organisation, 
no year).
Definitions of long- term opioid therapy vary widely. Most 
studies define long term as ≥90 days of opioid use, but the 
threshold ranges from 1 week to 1 year. Definitions also vary 
in terms of frequency of use (consistent daily dosing vs. inter-
mittent use) and if use is self- reported or based on dispensing 
records. Other definitions consider the dose as well as dura-
tion (Abdel Shaheed et al., 2019).
3 |  RESULTS
Replies were received from 18 councillors (Bosnia- 
Herzegovina, Croatia, Denmark, Estonia, Hungary, Italy, 
Kosovo, Latvia, Portugal, Republic of Ireland, Russia, Serbia, 
Slovenia, Slovakia, Spain, Sweden, Switzerland and United 
Kingdom) and from eight collaborators (Belgium, Czech 
Republic, Finland, France, Moldova, Norway, Slovenia and 
Ukraine) resulting in data from 25 European countries were 
received.
3.1 | Trends in opioid prescriptions
Bosetti et al., (2019) analysed data provided by International 
Narcotics Control Boards (INCB) on the consumption of 
prescribed fentanyl, oxycodone, morphine, hydromorphone 
and pethidine from 1990 to 2016 in 22 selected European 
countries. These data provide a comparable overview on the 
trends of prescriptions of strong opioids in Europe within one 
time period from 1990 to 2016. Therefore, we do not report 
on data provided by the councillors and collaborators for the 
period between 2000 and 2020, because these data used dif-
ferent opioids and time periods.
In most European countries except Estonia, Finland, 
Luxembourg and Ukraine, consumption of strong opioids in-
creased to a great extent between 2004– 2006 and 2014– 2016; 
it rose from 6,477 to 8,967 s- DDD (Consumption in defined 
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daily doses for statistical purposes; +38.4%) in the EU. The 
increase in opioid use was continuous since 2004 and it 
slowed down after the mid- to late 2000s in most European 
countries (see Table 1; Bosetti et al., 2019).
Data from the 2019 report by the International Narcotics 
Control Board show that the United States is the number 
one consumer of controlled substances, with 35, 140 DDDs 
of strong opioids per million inhabitants per day. In second 
place is Germany with 27, 419, followed by Canada with 22, 
402. The Netherlands is in 7th, Denmark is in 8th, Norway 
in 17th and Sweden in 21th place in the world (International 
Narcotics Control Board, 2020).
Twelve countries in our survey provided data on opi-
oid consumption since 2016. Four countries reported an 
increase: Estonia from 2014 to 2019; Portugal from 2009 
to 2019; Russia from 2014 to 2019 and Spain from 2017 
to 2019. Six countries reported a stable opioid consump-
tion: Lithuania and Slovakia from 2016 to 2019; Slovenia 
between 2017 and 2018; Belgium and Ireland between 
2017 and 2019 and United Kingdom from 2016 to 2017. 
Two countries reported a decrease: Denmark from 2016 
to 2019 and Finland from 2009 to 2019 (see electronic 
Supplementary Material 1).
3.2 | Indications for opioid therapy
Data from 10 countries were found. Seventy- five per cent to 
94% of opioids were prescribed for acute pain and chronic 
noncancer pain and 6% to 25% were prescribed for can-
cer pain. These are the data in detail for the percentages of 
opioid prescriptions for acute pain and /or CNCP (years of 
assessment in brackets): Belgium (2017): 92%; Denmark 
(2017): 92%; Estonia (2011– 2017): 86%; France (2017): 
78%; Germany (2010): 77%; Italy (2013): 82%; Netherlands 
(2017): 75%; Norway (2010): Ca. 90%; Switzerland (2006– 
2010): 94%; United Kingdom (2000– 2010): 84% (see elec-
tronic Supplementary Material 2).
3.3 | Long- term opioid therapy
Data from six countries were found. Different defini-
tions for long- term opioid therapy (LTOT) and reference 
population (all patients with chronic pain vs. patient with 
chronic noncancer pain) were used. The percentage of peo-
ple with LTOT in the general population ranged from 0.2% 
to 3.5%. These are the data in detail (years of assessment 
in brackets): Belgium (2017): 3%; Denmark (2013, 2017): 
3%, 2.7%; Germany (2012, 2014): 1.3%, 0.8%; Netherlands 
(2017): Ca. 2.5% to 3.5%; Spain (2015– 2018): 0.2%; United 
Kingdom (2015– 2018): 3% (see electronic Supplementary 
Material 3).
T A B L E  1  Total opioid consumption in European countries, the 
European Union and the United States in 2004– 2006 and 2014– 2016, 
and corresponding percent change (Bosetti et al., 2019)
s- DDD per 1,000,000 
inhabitants/day
% change 
2004- 06/2014- 16a 2004– 06
2014– 
16
Albania 58 268 359.8
Andorra 1,281 3,217 151.1
Austria 9,361 20,180 115.6
Belarus 36 337 839.9




Bulgaria 354 532 50.4
Croatia 1,396 1,815 30.0
Cyprus 429 1,885 339.8
Czech Republic 1,654 4,614 179.0
Denmark 9,915 12,166 22.7
Estonia 813 803 −1.3
Finland 6,458 5,591 −13.4
France 4,815 6,877 42.8
Germany 11,168 21,346 91.1
Gibraltar 2,403 14,698 511.6
Greece 2,184 7,892 261.4
Hungary 2,091 4,281 104.7
Iceland 4,576 8,162 78.3
Ireland 3,248 5,389 65.9
Italy 1,407 4,359 209.8
Latvia 675 1,652 144.7
Lithuania 686 1,360 98.2
Luxembourg 4,819 4,584 −4.9
Malta 317 492 55.5
Montenegro 0 1,706 — 
Netherlands 4,635 12,198 163.2
Norway 5,469 9,658 76.6
Poland 1,357 1,840 35.6
Portugal 1,701 3,596 111.4




Serbia 776 1,312 69.1
Slovakia 1,439 5,306 268.7
Slovenia 2,842 5,701 100.6
Spain 5,022 10,789 114.8
Sweden 5,408 9,084 68.0
Switzerland 5,899 11,850 100.9
(Continues)
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3.4 | Opioid- related emergency room visits 
due to intoxications with opioids
We found data of five European countries of which all re-
ported an increase: Denmark from 2017 to 2018:7.8%; 
Finland from 2009 to 2018: 318%; France from 2000 to 2017: 
167%; Netherlands (two studies): 2013 to 2017: 70.2% and 
2008 to 2017: 320%; United Kingdom from 2018 to 2019: 
6%. The increase in Denmark and United Kingdom did not 
meet the predefined criteria for a substantial increase. The 
French study included only prescription opioids. In England 
and Wales, 53% of hospital admissions were due to prescrip-
tion opioids. The remaining studies did not report on the 
percentage of prescription opioids. None of the studies re-
ported the percentage of fatal intoxications. No study pro-
vided data on the percentage of people with chronic pain and 
prescribed opioids with hospital admissions (see electronic 
Supplementary Material 4).
3.5 | Opioid- related deaths
We found data on opioid- related deaths for 13 countries. 
Austria (2003 to 2016), Estonia (2012 to 2017), Ireland (2006 
to 2017), Serbia (2012 to 2015) reported a decrease. Croatia 
(2015 to 2017) and Germany (2017 to 2019) reported a sta-
ble number of opioid- related deaths. Finland (2000 to 2018), 
France (2000 to 2015), Netherlands (2000 to 2014), Spain 
(2008 to 2017) and United Kingdom (2017 to 2018) reported 
an increase. Norway reported a decline in heroin- associated 
deaths, a variable/stable tendency for methadone, but an in-
crease for other opioids from 2008 to 2018. No statements 
were possible based on the Slovenian data.
The opioids which were most frequently detected on post- 
mortem evaluation differed by country (e.g. Estonia: fentanyl; 
Finland: buprenorphine and oxycodone; Scotland: heroin and 
methadone). There were large differences in opioid- related 
deaths per million inhabitants ranging from 1.5 in Finland, 3.2 
in France, up to 12 in the Netherlands and up to 234 in United 
Kingdom. We did not find data on the percentage of people with 
chronic pain and prescribed opioids in the numbers of opioid- 
related deaths (see electronic Supplementary Material 5).
3.6 | People referred to substance abuse 
disorder care services due to opioid use
Here, we report data which were not included in the European 
Drug Report 2019 (European Monitoring Centre for Drugs & 
Drug Addiction, 2019). We found data for six countries (see 
electronic Supplementary Material 6).
In England, the proportion of people starting treatment 
who reported heroin as their primary drug has decreased 
over the past decade, from 53% in 2009 to 45% in 2018. 
This decline was even more prominent among those who 
had never been treated before. Among people in continu-
ous treatment, the proportion reporting primary heroin use 
has remained stable, between 75% and 78% over the past 
decade.
In Finland, there was an increase in problematic opioid 
use from 32% to 74% from 2000 to 2018.
In France, there was an increase from 2.8% to 4.6% of 
patients with prescription opioids from 2006 to 2017.
In Germany, the number of people with opioid use dis-
order in contact with the German drug help system has re-
mained constant for the last 20 years.
In the Netherlands, the number of patients in depen-
dence care for opioid use disorders other than heroin in-
creased from 3.1 to 5.6 per 100,000 inhabitants from 2008 
to 2017.
We did not find data on the percentage of people with 
chronic pain and prescribed opioids in the numbers of people 
referred to substance use disorder care services.
4 |  DISCUSSION
4.1 | Summary of main results
We found a great variety in the quantity and quality of 
data available on prescription opioid use and a great im-
balance of prescribed opioid consumption in 25 European 
countries. We found a parallel increase in opioid prescrip-
tions and some proxies of opioid- related harms in France, 
Finland and the Netherlands but not in Germany, Norway 
and Spain. In the United Kingdom, opioid overdose deaths, 
but not opioid prescriptions increased between 2016 and 
2018. There are no robust data to confirm or refuse the 
assumption that the prescription of opioids for medical rea-
sons has contributed to opioid- related morbidity and mor-
tality in Europe.
s- DDD per 1,000,000 
inhabitants/day
% change 
2004- 06/2014- 16a 2004– 06
2014– 
16
Ukraine 93 66 −29.7
United Kingdom 3,021 8,214 171.9
European Union 6,477 8,967 38.4
United States of 
America
14,598 16,491 13.0
Abbreviation: s- DDD, defined daily doses for statistical purposes.
aPercent change was calculated on the real s- DDD values before rounding them 
for presentation.
T A B L E  1  (Continued)
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4.2 | Trends of opioid consumption 
in Europe
Opioid prescriptions have increased in nearly all European 
countries from 2006 to 2016. However, starting and end-
points of s- DDD are very different. s- DDD per 1,000,000 
inhabitants/day was 215- fold higher in Belgium than in 
Albania in 2004 to 2006 and 56- fold higher in 2014 to 
2016.
Data available for the years 2017 to 2019 give a het-
erogeneous picture. A decrease in prescriptions has been 
described in some countries with rather high consumption 
in the past such as Denmark and Finland. Opioid consump-
tion has increased in some countries with a previous low 
consumption such as Estonia, Portugal and Russia and well 
as in some countries with a previous high consumption 
such as Spain. It is important to note that there are regional 
inequalities of opioid prescribing, e.g. in different regions 
in Italy (Musazzi et  al.,  2018) and the United Kingdom 
(Curtis et al., 2019).
ATOME (Access To Opioid Medication in Europe), a 
project funded under the European Union's 7th Framework 
Programme and conducted between 2009 and 2014, found 
that in the 11 European countries with evidence of very 
low per capita morphine medicines consumption (Estonia, 
Latvia, Lithuania, Poland, Slovakia, Hungary, Slovenia, 
Serbia, Bulgaria, Greece and Cyprus) strict regulations and 
inappropriate policies had a negative impact on adequate 
access to opioid medicines (Radbruch et al., 2014). INCB 
data demonstrate an increase in opioid prescriptions in all 
of these countries (Bosetti et al., 2019). However, ATOME 
did not include some European countries with the lowest 
opioid medicines consumption. The comments from two 
collaborators highlight disparities in access to opioid med-
icines in Europe:
‘The opioid crisis in Moldova is rather due by “under-
prescription” of opioid analgesics for cancer pain relief 
and noncancer (cronic) pain relief’(Adrian Belei, personal 
communication).
‘Some opioids are registered in Kosovo which can be 
used with a doctor's prescription. This list was approved 
in January 2020, and in February it started to be imple-
mented, but due to the state of pandemics and the dysfunc-
tional health information system, we do not have accurate 
data on the description and use of all of them’. (Adem J. 
Bytyqi, pers. comm.).
4.3 | Indications for opioid therapy
The data available indicate that opioid analgesics are 
mainly prescribed for acute pain and CNCP in Western and 
Northern European countries. Long- term opioid treatment 
for CNCP is under debate globally because of the opi-
oid epidemic in the United States (Chou et  al.,  2020). In 
European guidelines, opioids remain a treatment option in 
carefully selected and supervised patients with CNCP for 
whom established non- pharmacological therapies and non- 
opioid analgesics have failed or have not been tolerated 
(Häuser et al., 2021; Petzke et al., 2020). The health claims 
data which have been used to find the indication for opioid 
prescriptions do not allow to draw conclusions if the indi-
cation was appropriate.
4.4 | Opioid- related 
morbidity and mortality
In 2017, specialist treatment services in Europe reported 
that 78% of all opioid clients presented for problems pri-
marily with heroin (European Monitoring Centre for Drugs 
& Drug Addiction, 2019). Scholten (2017) concluded from 
the European Drug Report 2017 that out of all people who 
seek treatment for opioid use disorder roughly 6% were on 
prescription opioids. He found no evidence in the European 
Drug Survey 2017 that opioids prescribed to patients with 
pain are problematic in Europe. There is some suggestion that 
methadone and buprenorphine on the illicit markets originate 
from patients in opioid agonist therapy (Scholten, 2017).
In contrast to the United States, fentanyl derivates do 
not yet appear to be a major driver of opioid use disorder 
across Europe. Only 0.5% people registering with drug treat-
ment services cite fentanyl and its derivates as their primary 
drug, although country- specific variations exist, with fen-
tanyl reported as the primary drug for the majority of en-
trants in Estonia (European Monitoring Centre for Drugs & 
Drug Addiction, 2019). Accordingly, the number of fentanyl- 
related fatal overdoses appears significantly lower in Europe 
compared with the United States (Ciccarone, 2019; Schifano 
et al., 2019). However, fentanyl- related mortality is increas-
ing in some countries: In England and Wales, there were 75 
fentanyl- related deaths were reported in 2017 and 74 deaths 
in 2018, a 29% increase from 2016 (Office for National 
Statistics, 2019).
This survey did not find data on the extent to which illicit 
use of opioids (without prescriptions), so- called prescription 
opioids and use of opioids prescribed for medical reasons 
but used by patients for unintended purposes (so- called pre-
scribed opioids; Scholten, 2017) contribute to opioid- related 
morbidity and mortality. It is important to note that prescribed 
opioids did not substantially contribute to fatal overdose 
in people prescribed with them in the United States. Only 
1.3% of opioid- related overdose decedents in Massachusetts 
during 2013– 2015, had an active prescription for each opioid 
detected in toxicology reports on the date of death (Walley 
et al., 2019).
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4.5 | Is Europe facing an Opioid crisis?
Jarlbaek analysed data on dispensed opioid prescriptions 
(ATC; N02A, and R05DA04) of three Scandinavian coun-
tries (Denmark, Norway and Sweden) during 2006– 2014, 
using public assessable prescription data. From 2006 to 
2014 the numbers of users/1,000 inhabitants increased 
from 98 to 105 in Norway, from 66 to 75 in Denmark and 
from 78 to 79 in Sweden, respectively. Within each coun-
try, the overall picture of opioid consumption appeared 
rather stable. The author concluded, there does not appear 
to be the emergence of an opioid epidemic in Denmark, 
Sweden or Norway judged by the statistics used in this 
study (Jarlbaek, 2019).
One study each conducted in France (Chenaf et al., 2019), 
Netherlands (Kalkman et al., 2019) and Spain (Salazar 
et al., 2020) found an increase in opioid prescription to 2017 
with several proxies for opioid- related morbidity showing 
a parallel increasing trend. All authors concluded that their 
country is far from the (prescription) opioid epidemic faced 
by the United States.
Rosner and colleagues conducted a systematic review of 
the epidemiology of opioid prescriptions in Germany and 
identified 18 studies from 1995 to 2016. The authors con-
cluded that the number of opioid prescriptions overall as well 
as the number of people receiving opioid treatment have in-
creased over time. Even though patterns of opioid prescrip-
tion follow trends observed in other developed countries, 
there are no signs of an opioid epidemic in Germany (Rosner 
et al., 2019).
Van Amsterdam studied recent trends in opioid prescrip-
tion rates, prevalence rates of fatal and non- fatal incidents 
and dependence care treatment were used as proxies of 
opioid- related harm in Germany, France and the Netherlands 
by a systematic search in different databases until April 2020. 
Considering that the use of prescription opioids has been 
declining rather than increasing in Europe, the authors con-
cluded that an opioid crisis is not anticipated yet in Europe 
(van Amsterdam et al., 2020).
Scotland has the highest rates of opioid- related emer-
gency visits deaths. Compared to France, Germany and the 
Netherlands, the rate of opioid- related overdoses is more than 
four times higher while the opioid use disorder treatments 
are three times lower (van Amsterdam et al., 2020). Opioid- 
related deaths per million inhabitants in the United Kingdom 
in 2019 were comparable to the ones in the United States in 
2018 with 206 opioid- related deaths per million inhabitants 
(Heedegard et al., 2020). UK authors have stated that the ris-
ing opioid- related deaths in England and Scotland have to 
be recognized as a public health crisis (Kimber et al., 2019). 
However, most of the increase in mortality in the United 
Kingdom relate to illicit heroin and methadone and not to 
opioids prescribed for pain. It is less certain if the number of 
ED attendances and overdose are related more to prescribed 
opioids.
The OECD concluded that higher rates of opioids pre-
scribed for medical reasons are not necessarily correlated 
with higher overdose death rates, for instance, in Germany, 
Austria, Belgium, Denmark and the Netherlands. This sug-
gests that an appropriate use and regulatory environment 
for prescription opioids can be compatible with having a 
higher availability of these medications for medical use 
(Organisation for Economic Co- operation & Development 
OECD, 2019).
4.6 | Limitations
We might have missed available data for some countries by 
our survey.
We have considered an increase in opioid use when a 
change >10% was observed in the time period analysed. 
During the same period (20 years) the population character-
istics may have changed and this 10% consumption increase 
may reflect it. We did not consider changes in population 
size when considering changes in the proxies of an opioid 
epidemic.
The comparability of the data on opioid consumption and 
opioid- related morbidity and mortality in European countries 
is limited because partially different opioids were included 
into analysis and different data sources were used.
INCB data are not based on surveys using prescriptions 
by pharmacies, wholesale and insurance companies, but 
on reports of the governments which use different data 
collection and reporting methods (International Narcotics 
Control Board, 2020). Tramadol, an opioid with an addi-
tional mode of action, and which is frequently prescribed in 
some European countries (e.g. Denmark, France, Germany, 
Norway, Poland and Sweden) and buprenorphine are not 
included in INCB statistics (van Amsterdam & van den 
Brink, 2015).
Data on emergency visits, substance disorder treatment 
admissions and drug- related deaths frequently include 
all drugs. If separate data for opioids are given, nearly all 
European data do not distinguish between prescribed, over- 
the- counter and illicitly obtained medicines and not be-
tween opioids prescribed for pain and substance use disorder 
management.
Our data do not provide insight in the content of illicit 
substances abused (e.g. fentanyl may be sold as heroin).
Available data only report on substances ‘mentioned’ on 
death certificates. It is unable to distinguish deaths caused by 
the substance or substances and those where the substance 
is present but did not contribute to the death, and does not 
identify whether the substance was legitimately obtained on 
prescription or over- the- counter or obtained illicitly.
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Data from substance dependence treatment services do 
not contain information about the start of the opioid use dis-
order (OUD). Therefore, no conclusion is possible that OUD 
started with a prescription for a medical opioid (Kalkman 
et  al.,  2019). Longitudinal data from five US commercial 
health plans between 2000 and 2005 demonstrated that pa-
tients with CNCP prescribed with opioids had significantly 
higher rates of OUD compared with those not prescribed with 
opioids. OR was 14.9 with chronic low dose use, OR 28.7 
with medium chronic dose use and OR 122.4 with chronic 
high dose. The absolute numbers of OUD were as follows: 
0.7% for chronic low dose (1– 36 MEQ/d), 1.3% for medium 
chronic dose (36 to 120 MEQ/d) and 6.1% for high chronic 
low dose (>120 MEQ/d; Edlund et al., 2014).
5 |  CONCLUSIONS
Based on the findings of this survey there is no clear indica-
tion that Europe is facing an opioid crisis to the extent as 
described in the United States. Recent data on rising opioid- 
related deaths in England and Scotland comparable to the 
United States have to be kept in mind. However, most of the 
increase in mortality in the United Kingdom relate to illicit 
heroin and methadone and not for opioids prescribed for pain.
When discussing an opioid crisis associated with opi-
oids designed for medical use, a clear distinction should be 
made between prescription opioids and prescribed opioids 
(Scholten,  2017). There are no robust data to confirm or 
refuse the assumption, that the prescription of opioids for 
medical reasons has contributed to opioid- related morbidity 
and mortality in Europe. Studies are necessary to assess if 
patients with opioids prescribed for chronic pain play a rele-
vant role in the diversion of illicitly used prescribed opioids.
The relatively common lack of formal national data on use 
and non- medical use of opioids, emergency room admissions 
and number of patients on opioids in the general population 
in several European countries requires a better standardiza-
tion in Europe.
Some of the existing criteria for substance dependence 
(ICD 10, ICD 11, Diagnostic and Statistical Manual for 
Psychiatric Diseases [DSM] 5) and opioid use disorder are 
inappropriate for patients prescribed with opioids for chronic 
pain: They make no distinction between pain- related and 
non- pain- related symptoms and thus overestimate the preva-
lence of opioid dependence (Elander et al., 2003) and opioid 
use disorder. New criteria have to designed in the collabora-
tion of psychiatry and pain medicine.
European health and regulatory authorities should be 
aware that discussions on the European opioid crisis do not 
increase the obstacles to opioid medication for cancer ther-
apy and palliative care in some Eastern Europe countries 
(Scholten & Henningfield, 2016).
Countries should take actions to reach and maintain an 
appropriate balance to cover the real needs for pain relief 
without exposing patients to the threat of opioid use disorder 
development (Organisation for Economic Co- operation & 
Development OECD, 2019). Education of patients and health 
care professionals on appropriate use of opioids for acute, 
cancer and noncancer pain should be provided by medical 
associations and training courses. EFIC has published clini-
cal practice recommendations on the (limited) role of opioids 
for and their appropriate use in CNCP (Häuser et al., 2021; 
Krcevski- Škvarc et al. 2021).
The most popular narrative about the US opioid crisis 
claims that it started by prescribing of opioids to patients with 
chronic pain by unscrupulous and mercenary physicians in-
fluenced by pharmaceutical companies. Although uncritical 
prescription of opioids was a key factor in the first period of 
the US crisis, it was fundamentally fuelled by economic and 
social problems. Opioids were prescribed as a shelter from 
physical and psychological trauma and social discriminations 
(Dasgupta et al., 2018; deWeerdt, 2019). Europe as a whole 
is prompted to counterbalance socioeconomic disparities as 
much as possible.
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